UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 118

Sortiert nach

A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling

Bone (New York, N.Y.), 2010-01, Vol.46 (1), p.49-63

2010

Volltextzugriff (PDF)

Quantitative Systems Pharmacology and Physiologically‐Based Pharmacokinetic Modeling With mrgsolve: A Hands‐On Tutorial

CPT: pharmacometrics and systems pharmacology, 2019-12, Vol.8 (12), p.883-893

2019

Volltextzugriff (PDF)

When Learn/Confirm Leads to Expand/Understand: The Expanding Role of Quantitative Systems Pharmacology in the Betterment of Therapeutics Development

Clinical pharmacology and therapeutics, 2019-03, Vol.105 (3), p.558-560

Riggs, Matthew M.

2019

Volltextzugriff (PDF)

Pharmacometrics and systems pharmacology for metabolic bone diseases

British journal of clinical pharmacology, 2019-06, Vol.85 (6), p.1136-1146

2019

Volltextzugriff (PDF)

A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes

Pharmaceutics, 2021-04, Vol.13 (4), p.485

2021

Volltextzugriff (PDF)

Quantification of the Impact of Partition Coefficient Prediction Methods on Physiologically Based Pharmacokinetic Model Output Using a Standardized Tissue Composition

Drug metabolism and disposition, 2020-10, Vol.48 (10), p.903-916

2020

Volltextzugriff (PDF)

Toward Progress in Quantitative Translational Medicine: A Call to Action

Clinical pharmacology and therapeutics, 2020-01, Vol.107 (1), p.85-88

2020

Volltextzugriff (PDF)

Training the next generation of pharmacometric modelers: a multisector perspective

Journal of pharmacokinetics and pharmacodynamics, 2024-02, Vol.51 (1), p.5-31

2024

Volltextzugriff (PDF)

Correction to: Training the next generation of pharmacometric modelers: a multisector perspective

Journal of pharmacokinetics and pharmacodynamics, 2024-02, Vol.51 (1), p.89-89

2024

Volltextzugriff (PDF)

Low‐dose empagliflozin as adjunct‐to‐insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy

Diabetes, obesity & metabolism, 2020-03, Vol.22 (3), p.427-433

2020

Volltextzugriff (PDF)

Model-based meta-analysis for comparing Vitamin D2 and D3 parent-metabolite pharmacokinetics

Journal of pharmacokinetics and pharmacodynamics, 2017-08, Vol.44 (4), p.375-388

2017

Volltextzugriff (PDF)

A model of fracture risk used to examine the link between bone mineral density and the impact of different therapeutic mechanisms on fracture outcomes in patients with osteoporosis

Journal of pharmacokinetics and pharmacodynamics, 2017-12, Vol.44 (6), p.599-609

2017

Volltextzugriff (PDF)

Model-based meta-analysis for development of a population-pharmacokinetic (PPK) model for Vitamin D3 and its 25OHD3 metabolite using both individual and arm-level data

Journal of pharmacokinetics and pharmacodynamics, 2016-04, Vol.43 (2), p.191-206

2016

Volltextzugriff (PDF)

Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes

Journal of clinical pharmacology, 2013-10, Vol.53 (10), p.1028-1038

2013

Volltextzugriff (PDF)

A Priori Identifiability of Target-Mediated Drug Disposition Models and Approximations

The AAPS journal, 2015-09, Vol.17 (5), p.1280-1284

2015

Volltextzugriff (PDF)

Multiscale Physiology-Based Modeling of Mineral Bone Disorder in Patients With Impaired Kidney Function

Journal of clinical pharmacology, 2012-01, Vol.52 (S1), p.45S-53S

2012

Volltextzugriff (PDF)

Exposure−response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes

British journal of clinical pharmacology, 2014-12, Vol.78 (6), p.1407-1418

2014

Volltextzugriff (PDF)

Facilitating pharmacometric workflow with the metrumrg package for R

Computer methods and programs in biomedicine, 2013-01, Vol.109 (1), p.77-85

2013

Volltextzugriff (PDF)

Population Pharmacokinetics and Exposure-Response of Albinterferon Alfa-2b

Journal of clinical pharmacology, 2012-04, Vol.52 (4), p.475-486

2012

Volltextzugriff (PDF)

T2008 Population Pharmacokinetics and Exposure-Response of Albinterferon Alfa-2B

Gastroenterology (New York, N.Y. 1943), 2010, Vol.138 (5), p.S-848-S-848

2010

Volltextzugriff (PDF)

Clinical Trial Simulation: Efficacy Trials

Pharmacometrics, 2007, p.881-900

2007

Volltextzugriff (PDF)

Population Pharmacokinetics/Pharmacodynamics and Individualized Drug Therapy: Parameters describing pharmacologic effect as a function of drug concentration can help pharmacists develop individualized doses and dosing schedules

Journal of the American Pharmaceutical Association (1996), 1997-01, Vol.37 (1), p.59-61

Riggs, Matthew M

1997

Volltextzugriff (PDF)

Population Pharmacokinetics/Pharmacodynamics and Individualized Drug Therapy: Parameters describing pharmacologic effect as a function of drug concentration can help pharmacists develop individualized doses and dosing schedules

Journal of the American Pharmaceutical Association (1961), 1997-01, Vol.37 (1), p.59-61

Riggs, Matthew M

1997

Volltextzugriff (PDF)

Population pharmacokinetics/pharmacodynamics and individualized drug therapy

Journal of the American Pharmaceutical Association (1996), 1997-01, Vol.NS37 (1), p.59-61

Riggs, M M

1997

Volltextzugriff (PDF)

Hole‐Transfer Dependence on Blend Morphology and Energy Level Alignment in Polymer: ITIC Photovoltaic Materials

Advanced materials (Weinheim), 2018-01, Vol.30 (3), p.n/a

2018

Volltextzugriff (PDF)

1 – 25 von 118

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(105)
Mit Volltextzugriff
(104)

Publikationsform

Sprache

Englisch
(118)
Japanisch
(14)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling

Quantitative Systems Pharmacology and Physiologically‐Based Pharmacokinetic Modeling With mrgsolve: A Hands‐On Tutorial

When Learn/Confirm Leads to Expand/Understand: The Expanding Role of Quantitative Systems Pharmacology in the Betterment of Therapeutics Development

Pharmacometrics and systems pharmacology for metabolic bone diseases

A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes

Quantification of the Impact of Partition Coefficient Prediction Methods on Physiologically Based Pharmacokinetic Model Output Using a Standardized Tissue Composition

Toward Progress in Quantitative Translational Medicine: A Call to Action

Training the next generation of pharmacometric modelers: a multisector perspective

Correction to: Training the next generation of pharmacometric modelers: a multisector perspective

Low‐dose empagliflozin as adjunct‐to‐insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy

Model-based meta-analysis for comparing Vitamin D2 and D3 parent-metabolite pharmacokinetics

A model of fracture risk used to examine the link between bone mineral density and the impact of different therapeutic mechanisms on fracture outcomes in patients with osteoporosis

Model-based meta-analysis for development of a population-pharmacokinetic (PPK) model for Vitamin D3 and its 25OHD3 metabolite using both individual and arm-level data

Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes

A Priori Identifiability of Target-Mediated Drug Disposition Models and Approximations

Multiscale Physiology-Based Modeling of Mineral Bone Disorder in Patients With Impaired Kidney Function

Exposure−response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes

Facilitating pharmacometric workflow with the metrumrg package for R

Population Pharmacokinetics and Exposure-Response of Albinterferon Alfa-2b

T2008 Population Pharmacokinetics and Exposure-Response of Albinterferon Alfa-2B

Clinical Trial Simulation: Efficacy Trials

Population Pharmacokinetics/Pharmacodynamics and Individualized Drug Therapy: Parameters describing pharmacologic effect as a function of drug concentration can help pharmacists develop individualized doses and dosing schedules

Population Pharmacokinetics/Pharmacodynamics and Individualized Drug Therapy: Parameters describing pharmacologic effect as a function of drug concentration can help pharmacists develop individualized doses and dosing schedules

Population pharmacokinetics/pharmacodynamics and individualized drug therapy

Hole‐Transfer Dependence on Blend Morphology and Energy Level Alignment in Polymer: ITIC Photovoltaic Materials

Suchergebnisse filtern